Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®
Tergase® poised to capture a fair share of the global hyaluronidase market. DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced that the Ministry of Food and Drug Safety (MFDS) of Korea approved its New Drug Application (NDA) for Tergase® (recombinant hyaluronidase). Tergase® is a recombinant human hyaluronidase developed utilizing Alteogen's proprietary Hybrozyme™ Technology. Dermal...
GEN Z TAKING PROACTIVE STEPS TO ADDRESS MENTAL HEALTH ISSUES
Yet youth body confidence, ADHD and general lack of purpose abound according to new research SYDNEY, July 8, 2024 /PRNewswire/ -- More than half of Gen Zs are increasingly seeking out mental health therapy indicating support is needed for an entire generation of Australians plagued by anxiety and depression, according to a national...
Cambrex to Expand Stability Storage Business with New Facility in Durham, North Carolina
EAST RUTHERFORD, N.J., July 8, 2024 /PRNewswire/ -- Cambrex today announced the expansion of its stability storage business, Q1 Scientific, which offers environmentally-controlled stability storage services to the pharmaceutical, medical device, and life sciences industries. Q1 Scientific will open a new state-of-the-art facility in Durham, North Carolina before the end of...
DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer’s Disease
BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer's disease (AD). AD is the most frequent cause of dementia (60%~70%), affecting approximately 57 million people worldwide. Neurovascular dysfunction is an early...
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME
The nomination of novel Lp-PLA2 inhibitor DPT0415 for the treatment of DR & DME. DPT0415 is a highly potent, selective and safe Lp-PLA2 inhibitor with sufficient target engagement at a dose of 0.3 mpk and robust efficacy in the STZ-induced rat DR model. This project further validates the capabilities of DP Technology's drug design platform RiDYMO. BEIJING, July...
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for JCXH-211 intravenous (IV), a novel, first-in-class self-replicating mRNA (srRNA) encoding the engineered human interleukin...
Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics
HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the interim results for successful completion of the second cohort of its Phase I clinical study of GalNAc-based...
Parents: Discover the Three Essential Pillars of Childcare for Your Child’s Optimal Development
JAKARTA, Indonesia, July 2, 2024 /PRNewswire/ -- Morinaga Milk is unveiling the three key pillars of childcare under its latest campaign: Potential-Attention-Nutrition. As a leading brand under Kalbe Nutritionals, Morinaga is launching this campaign to help 21st century parents meet the challenges of raising children amid rapid technological advancements and societal changes. Studies show that many parents have not...
BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial
SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-blind, placebo-controlled, dose-ranging phase 2 clinical trial of SC0062 in chronic kidney disease (CKD). The study is ongoing in the diabetic kidney disease (DKD) cohort. SC0062...
Resounding Success! Hi & Fi Asia-China 2024 Hits Historic Highs
Hi & Fi Asia-China Concludes with Record Attendance and Strong International Participation. SHANGHAI, July 8, 2024 /PRNewswire/ -- The 25th Hi & Fi Asia-China, China's leading trade fair for healthy and natural food ingredients, concluded on a high note, with record-breaking attendance figures and strong international participation. The 3-day exhibition attracted 15,743 visitors from 79 countries, exceeding attendance...
